Press release
Gaucher's disease Pipeline Drugs and Companies Insight Report (2023): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Gaucher's disease Overview
Gaucher disease is a rare, inherited metabolic disorder in which deficiency of the enzyme glucocerebrosidase results in the accumulation of harmful quantities of certain fats (lipids), specifically the glycolipid glucocerebroside, throughout the body especially within the bone marrow, spleen and liver. The symptoms and physical findings associated with Gaucher disease vary greatly from patient to patient.
"Gaucher's disease Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Gaucher's disease Market.
The Gaucher's disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Gaucher's disease Pipeline Report: https://www.delveinsight.com/report-store/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Gaucher's disease treatment therapies with a considerable amount of success over the years. Gaucher's disease Key players such as - Gain therapeutics, M6P Therapeutics, AvroBio, Orphazyme, Eli Lilly and Company, Sanofi, and others, are developing therapies for the Gaucher's disease treatment
• Gaucher's disease Emerging therapies such as - GBA programme, M 011, AVR-RD-02, Arimoclomol, GBA1 Gene Therapy, Venglustat, and others are expected to have a significant impact on the Gaucher's disease market in the coming years.
• In April 2022, Sanofi initiated a parallel arm, Phase 3, double-blind, active-comparator, 2 arm study to evaluate the efficacy and safety of daily oral venglustat versus intravenous Cerezymeinfusions every two weeks for improvement or stabilization of the neurological manifestations and maintenance of systemic disease stability in participants aged ≥12 and adult patients with Gaucher disease Type 3 (GD3) who have been treated with Enzyme Replacement Therapy (ERT) for at least 3 years
Gaucher's disease Pipeline Therapeutics Assessment
• Gaucher's disease Assessment by Product Type
• Gaucher's disease By Stage and Product Type
• Gaucher's disease Assessment by Route of Administration
• Gaucher's disease By Stage and Route of Administration
• Gaucher's disease Assessment by Molecule Type
• Gaucher's disease by Stage and Molecule Type
DelveInsight's Gaucher's disease Report covers around 16+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Gaucher's disease Drugs Under Different Phases of Clinical Development Include:
• GBA programme: Gain therapeutics
• M 011: M6P Therapeutics
• AVR-RD-02: AvroBio
• Arimoclomol: Orphazyme
• GBA1 Gene Therapy: Eli Lilly and Company
• Venglustat: Sanofi
Get a Free Sample PDF Report to know more about Gaucher's disease Pipeline Assessment- https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gaucher's disease Pipeline Analysis:
The Gaucher's disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Gaucher's disease treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Gaucher's disease Treatment.
• Gaucher's disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Gaucher's disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Gaucher's disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Gaucher's disease product details are provided in the report. Download the Gaucher's disease pipeline report to learn more about the emerging Gaucher's disease therapies at:
https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Gaucher's disease Pipeline Market Drivers
• Increasing investment for healthcare infrastructure
• Rising prevalence of lysosomal disease
Gaucher's disease Pipeline Market Barriers
• High cost associated with the treatment
• Lack of awareness among people in developing countries
Scope of Gaucher's disease Pipeline Drug Insight
• Coverage: Global
• Key Gaucher's disease Companies: Gain therapeutics, M6P Therapeutics, AvroBio, Orphazyme, Eli Lilly and Company, Sanofi, and others
• Key Gaucher's disease Therapies: GBA programme, M 011, AVR-RD-02, Arimoclomol, GBA1 Gene Therapy, Venglustat, and others
• Gaucher's disease Therapeutic Assessment: Gaucher's disease current marketed and Gaucher's disease emerging therapies
• Gaucher's disease Market Dynamics: Gaucher's disease market drivers and Gaucher's disease market barriers
Request for Sample PDF Report for Gaucher's disease Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Gaucher's disease Report Introduction
2 Gaucher's disease Executive Summary
3 Gaucher's disease Overview
4 Gaucher's disease- Analytical Perspective In-depth Commercial Assessment
5 Gaucher's disease Pipeline Therapeutics
6 Gaucher's disease Late Stage Products (Phase II/III)
7 Gaucher's disease Mid Stage Products (Phase II)
8 Gaucher's disease Early Stage Products (Phase I)
9 Gaucher's disease Preclinical Stage Products
10 Gaucher's disease Therapeutics Assessment
11 Gaucher's disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Gaucher's disease Key Companies
14 Gaucher's disease Key Products
15 Gaucher's disease Unmet Needs
16 Gaucher's disease Market Drivers and Barriers
17 Gaucher's disease Future Perspectives and Conclusion
18 Gaucher's disease Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Gaucher's disease drugs and therapies- https://www.delveinsight.com/sample-request/gauchers-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Gaucher's disease Market https://www.delveinsight.com/report-store/gauchers-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gaucher's disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Gaucher's disease Epidemiology https://www.delveinsight.com/report-store/gauchers-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Gaucher's disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Related Reports By DelveInsight -
Hypertrophic Scar Market
https://www.delveinsight.com/report-store/hypertrophic-scar-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Hypertrophic Scar Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Lung Fibrosis Market https://www.delveinsight.com/report-store/lung-fibrosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Lung Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Lung Fibrosis, historical and forecasted epidemiology as well as the Lung Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Anterior Uveitis Market https://www.delveinsight.com/report-store/anterior-uveitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Anterior Uveitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Anterior Uveitis, historical and forecasted epidemiology as well as the Anterior Uveitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
22q11.2 deletion syndrome Market https://www.delveinsight.com/report-store/22q112-deletion-syndrome-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "22q11.2 Deletion Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the 22q11.2 Deletion Syndrome, historical and forecasted epidemiology as well as the 22q11.2 Deletion Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
X-Linked Retinitis Pigmentosa (XLRP) Market https://www.delveinsight.com/report-store/x-linked-retinitis-pigmentosa-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "X-Linked Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the X-Linked Retinitis Pigmentosa (XLRP), historical and forecasted epidemiology as well as the X-Linked Retinitis Pigmentosa market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Gaucher's disease Pipeline Drugs and Companies Insight Report (2023): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments here
News-ID: 2910491 • Views: …
More Releases from DelveInsight Business Research
Waldenstrom Macroglobulinemia Market Analysis 2034 - Competitive Landscape, Clin …
Waldenström macroglobulinemia (WM) is a rare, slow-developing non-Hodgkin lymphoma characterized by abnormal B-cell growth in the bone marrow and excessive production of IgM protein. In 2023, around 3,190 new cases were reported across the 7MM, with the US contributing about 40%. The disease is more common in males, and nearly half of cases occur in individuals over 65 due to genetic and age-related factors, including the MYD88 L265P mutation found…
Wilson's Disease Market Analysis 2034 - Competitive Landscape, Clinical Trials, …
DelveInsight reports that approximately 8,000 diagnosed prevalent cases of Wilson's Disease were recorded in the 7MM in 2023, with numbers projected to rise through 2034. The United States leads the market with a 2023 valuation of about USD 126 million, expected to grow at a CAGR of 13%. Current treatment mainly involves chelating agents and zinc salts, with chelating agents dominating the U.S. market at around USD 123 million. Recent…
Biktarvy Market and Sales Forecast: Strong Global Adoption, Expanding Indication …
DelveInsight, a leading business intelligence and market research firm, announced the publication of its latest report, "Biktarvy Market Insights, Sales Forecast, and Competitive Landscape - 2034." The report provides an in-depth commercial, clinical, and strategic outlook on Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide), reinforcing its continued leadership as one of the most widely prescribed HIV therapies worldwide.
As global healthcare systems increasingly adopt simplified antiretroviral regimens to improve adherence and long-term viral suppression, Biktarvy…
Global Biologics Contract Manufacturing Market to reach USD 47,494.63 million at …
According to DelveInsight's analysis, The increasing incidence of chronic conditions such as cancer, diabetes, and autoimmune diseases is driving the demand for biologic therapies, prompting pharmaceutical companies to outsource large-scale production to contract manufacturers. Additionally, the expanding pipeline of biologics-including monoclonal antibodies, vaccines, and biosimilars-necessitates adaptable manufacturing solutions to address rising market demand efficiently. Moreover, advancements in biotechnology and biomedical techniques, such as recombinant DNA technology and enhanced expression systems,…
More Releases for Gaucher
Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market - Restoring Bal …
Newark, New Castle, USA: The "Gaucher & Pompe Diseases Enzyme Replacement Therapy (ERT) Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Gaucher & Pompe Diseases Enzyme Replacement…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Treatment Market Size | Share | Growth Analysis 2022
The global gaucher disease treatment market size was valued at USD 1,522.3 million in 2021 and is poised to grow at a significant CAGR of 1.2% during the forecast period 2022-28. Gaucher disease is a rare genetic disorder that affects the body's ability to break down a certain type of fat called glucocerebroside. This build-up of fat can cause a range of symptoms, including enlarged organs, bone pain, anemia, and…
Gaucher Disease Market Revenue Data Historic and Forecast Analysis
The market for Gaucher disease was estimated at USD 980.0 million in 2021, and it is anticipated to grow at a CAGR of 8.5% to reach around USD 1,800.0 million in 2029.
The rising prevalence of Gaucher disease, increasing awareness about Gaucher disease, and upsurge in the number of approved therapies for the treatment of Gaucher disease. Even it is the most prevalent lysosomal storage disorder, Gaucher disease is a rare…
Gaucher Disease Market Size by 2025: QY Research
This recently published report examines the global Gaucher Disease market for the projected period of 7-years, i.e. between 2018 and 2025. The report highlights the accomplishments and opportunities lies in the market throughout the forecasted period. The report offers the thorough information about the overview and the scope of the global Gaucher Disease market along with its drivers, restraints, and trends. It also classifies the market into different segments such…
Gaucher Disease Market Pharmaceuticals & Healthcare Analysis 2018 to 2025
In 2017, the global Gaucher Disease market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025.
Companies Mentioned are:
Sanofi, Shire, Actelion Pharma, Pfizer, ISU Pharm, ....
Sample/Inquiry at:
https://www.marketinsightsreports.com/reports/0905827183/global-gaucher-disease-market-size-status-and-forecast-2018-2025/inquiry?Source=openpr&mode=47
Further, the market is segmented based on the applications, types and Geography area such as
Gaucher Disease Market, by Types:
Enzyme Replacement Therapy
Substrate Reduction Therapy
Gaucher Disease Market, by Applications:
Non-Neuronopathic Gaucher Disease
Neuronopathic Gaucher Disease
Geographically,…
